Thomas Zaramboukas
Overview
Explore the profile of Thomas Zaramboukas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kiryttopoulos A, Evangeliou A, Katsanika I, Boukovinas I, Foroglou N, Zountsas B, et al.
Front Nutr
. 2025 Mar;
11:1489812.
PMID: 40041752
Introduction: Glioblastoma multiforme (GBM) ranks as one of the most aggressive primary malignant tumor affecting the brain. The persistent challenge of treatment failure and high relapse rates in GBM highlights...
2.
Tzotzas T, Goropoulos A, Karras S, Terzaki A, Siolos A, Doumas A, et al.
Hormones (Athens)
. 2022 Jan;
21(1):171-176.
PMID: 34993886
Parathyromatosis is a rare cause of persistent or recurrent primary hyperparathyroidism and hypercalcemia due to the presence of hyperfunctioning foci of parathyroid tissue in the neck and/or mediastinum. We describe...
3.
Lambrou I, Ioannidis O, Manztoros I, Tatsis D, Chasampalioti M, Varnalidis I, et al.
Ann Ital Chir
. 2021 Sep;
92:424-434.
PMID: 34524115
Aim: Growth hormone is known to affect healing on the postoperative patient. The aim of the present experimental study was to evaluate the effect of systematic infusion of growth hormone...
4.
Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, et al.
Breast Cancer
. 2021 Jul;
28(6):1367-1382.
PMID: 34304347
Purpose: The genomic status of non-malignant tissues from carriers of pathogenic germline BRCA1/2 (gBRCA1/2) variants may reveal information towards individualized prophylaxis. We performed spatiotemporal tissue genotype comparisons in a real-life...
5.
Linardou H, Kotoula V, Kouvatseas G, Mountzios G, Karavasilis V, Samantas E, et al.
Cancer Genomics Proteomics
. 2019 Oct;
16(6):531-541.
PMID: 31659106
Background/aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients...
6.
Zafrakas M, Papasozomenou P, Eskitzis P, Zouzoulas D, Boulogianni G, Zaramboukas T
Case Rep Surg
. 2019 May;
2019:2327892.
PMID: 31093413
Hemangiomas are vascular lesions, which are only rarely located in the breast. Larger breast hemangiomas may be detected by clinical examination, mammography, and breast ultrasound, whereas smaller lesions are usually...
7.
Goussia A, Simou N, Zagouri F, Manousou K, Lazaridis G, Gogas H, et al.
PLoS One
. 2018 Aug;
13(7):e0200302.
PMID: 30063723
Several studies support an important role of angiogenesis in breast cancer growth and metastasis. The main objectives of the study were to investigate the immunohistochemical expression of vascular endothelial growth...
8.
Fountzilas G, Psyrri A, Giannoulatou E, Tikas I, Manousou K, Rontogianni D, et al.
Int J Cancer
. 2017 Sep;
142(1):66-80.
PMID: 28857155
Genomic patterns of nasopharyngeal carcinomas (NPCs) have as yet been studied in Southeast Asian (SEA) patients. Here, we investigated genomic patterns of locally advanced NPC Southeast European (SEE) patients treated...
9.
Grigoriou M, Kofina K, Ioannidis A, Gerasimidou D, Efthymiadis C, Zaramboukas T
Am J Case Rep
. 2017 Jul;
18:830-833.
PMID: 28743856
BACKGROUND Kaposi sarcoma is a malignancy commonly linked to HIV infection or immunosuppression. An association with human herpes virus 8 (HHV-8) infection has also been reported. We present a case...
10.
Koletsas N, Koletsa T, Choidas S, Anagnostopoulos K, Touloupidis S, Zaramboukas T, et al.
Patholog Res Int
. 2017 Feb;
2017:6794150.
PMID: 28210516
. Several investigators have suggested the possibility that the expression of both EGFR and HER2 could be utilized for molecularly targeted therapy in urinary bladder cancer. We tried to evaluate...